cl 387785 and thiopental sodium

cl 387785 has been researched along with thiopental sodium in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barf, T; Kaptein, A	1
Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ	1
Nakagawa, T; Yano, S	1

Reviews

1 review(s) available for cl 387785 and thiopental sodium

Article	Year
Irreversible protein kinase inhibitors: balancing the benefits and risks. Journal of medicinal chemistry, 2012, Jul-26, Volume: 55, Issue:14 Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors	2012

Other Studies

2 other study(ies) available for cl 387785 and thiopental sodium

Article	Year
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17 Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship	2013
The current state of molecularly targeted drugs targeting HGF/Met. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:1 Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2	2014

Article

Year

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17

Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship

2013

The current state of molecularly targeted drugs targeting HGF/Met.

Japanese journal of clinical oncology, 2014, Volume: 44, Issue:1

Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2

2014